Mylan Reveals FDA Goal Date For Bevacizumab

Mylan And Biocon Weighing Up A Third Biosimilar Launch

 
• By Dean Rudge

Mylan and Biocon's global development alliance has so far led to two biosimilar launches in the US. A filing for a biosimilar of Genentech's Avastin (bevacizumab) submitted by Mylan may soon bring a third.

Thumbs up
Mylan's bevacizumab filing has been accepted for filing by the FDA • Source: Shutterstock

More from Biosimilars

More from Products